I am delighted and honored that our consortium PALSTICITY-TX has been shortlisted for a #CancerGrandChallenge award. I am happy to lead this multidisciplinary team that ultimately wants to target tumor plasticity. Grateful to our team members for their collaborative effort!

👏 L’équipe de Cedric Blanpain sélectionnée pour la finale du prix Cancer Grand Challenges. Jusqu'à 25 millions de dollars à gagner pour mener leur projet sur la plasticité cellulaire dans le cancer 🔬 Résulats en mars 2024 ! #CancerGrandChallenges Université libre de Bruxelles ➡️ow.ly/veLM50PHHfx

💫NEW REVIEW ARTICLE Nature Cancer “Cancer cell plasticity during tumor progression, metastasis and response to therapy” by Cedric Blanpain
Andrea Pérez González & Co.

Read it here👇
nature.com/articles/s4301…
rdcu.be/djQTp

Why do MarieSkłodowskaCurie doctoral networks only fund 3 year PhD positions? Surely funding 4 years would be better, who can finish a life science PhD in 3 years?

Was a pleasure to co-author this review with Andrea and Kevin. Thanks to both of you. Hope our colleagues will enjoy reading it.

Thanks to the ⁦European Research Council (ERC)⁩ ⁦F.R.S.-FNRS⁩ ⁦Le Télévie⁩ ⁦WEL Research Institute⁩ #EOS - FNRS/FWO for supporting this research! nature.com/articles/s4158…

also a Clinical Briefing nature.com/articles/d4158…

more targeting EMT nature.com/articles/s4158…

Blockade of netrin-1 is a promising strategy against endometrial cancer

#MedTwitter go.nature.com/45fVNxj

new out in Nature, targeting EMT
nature.com/articles/s4158…

Cancer : un nouveau médicament pour diminuer les métastases et la résistance à la chimiothérapie rtbf.be/article/cancer… Cedric Blanpain Université libre de Bruxelles ULB ComRecherche CNRS 🌍

Hope that this new approach targeting EMT will now be helpful for the treatment of patients with cancers. Congratulations to our collaborators from the University of Lyon and Netris Pharma. Thanks to all our colleagues that contributed to this work.

nature.com/articles/s4158…

In a companion paper @nature, we show that administration of the antibody against Netrin-1 inhibits EMT in patients with endometrial cancers. Great to see our basic discovery translates into a therapy that can be used to target EMT in cancer patients nature.com/articles/s4158…

Congratulations to the first authors Justine Lengrand, Ievgenia Pastushenko and Sebastiaan (Seb) Vanuytven and all
our colleagues for their fantastic job. Thanks to Patrick Mehlen and our
collaborators from Netris Pharma that developed the
antibody targeting Netrin-1 nature.com/articles/s4158…

Delighted to share our new publication in @nature describing the first pharmacological approach that targets EMT, decreases metastasis and sensitizes cancer cells to chemotherapy in preclinical models of tumor with EMT nature.com/articles/s4158…

Beyond proud to share my first (co-)first author manuscript out today in #Nature , where we describe the inhibition of epithelial-to-mesenchymal transition ( #EMT ) by pharmacological targeting of netrin-1 (1/23)
nature.com/articles/s4158…

I’ve been super into the idea of intracellular molecular recording to measure cell dynamics, but this tech offers an interesting alternative: make the cells give you a sample!

Stanley Clarke N’4ever. ⁦NN North Sea Jazz Festival⁩

John McLaughlin’s, Shakti Featuring Zakir Hussain and Shankar Mahadevan ⁦NN North Sea Jazz Festival⁩

Brad Mehldau trio ⁦NN North Sea Jazz Festival⁩